Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Non-Current Liabilities: 2010-2025

Historic Other Non-Current Liabilities for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $761,000.

  • Anika Therapeutics' Other Non-Current Liabilities fell 5.58% to $761,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $761,000, marking a year-over-year decrease of 5.58%. This contributed to the annual value of $772,000 for FY2024, which is 91.09% up from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Other Non-Current Liabilities is $761,000, which was up 0.66% from $756,000 recorded in Q2 2025.
  • Anika Therapeutics' Other Non-Current Liabilities' 5-year high stood at $16.9 million during Q2 2021, with a 5-year trough of $398,000 in Q4 2022.
  • Over the past 3 years, Anika Therapeutics' median Other Non-Current Liabilities value was $407,000 (recorded in 2024), while the average stood at $568,545.
  • As far as peak fluctuations go, Anika Therapeutics' Other Non-Current Liabilities crashed by 96.53% in 2022, and later spiked by 101.50% in 2024.
  • Over the past 5 years, Anika Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $1.3 million in 2021, then plummeted by 68.36% to $398,000 in 2022, then grew by 1.51% to $404,000 in 2023, then skyrocketed by 91.09% to $772,000 in 2024, then decreased by 5.58% to $761,000 in 2025.
  • Its last three reported values are $761,000 in Q3 2025, $756,000 for Q2 2025, and $744,000 during Q1 2025.